Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.

about

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.

P2860

Q42324368-A3E713DD-6BD4-49C3-B05F-9D23289FC203

P2860

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.

Item

http://www.wikidata.org/entity/Q38992068

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Alicaforsen: An Emerging Thera ...... itis and Refractory Pouchitis.

@en

type

Item

label

Alicaforsen: An Emerging Thera ...... itis and Refractory Pouchitis.

@en

prefLabel

Alicaforsen: An Emerging Thera ...... itis and Refractory Pouchitis.

@en

P1476

Alicaforsen: An Emerging Thera ...... itis and Refractory Pouchitis.

@en

P2093

Gang Liu

http://www.w3.org/2001/XMLSchema#string

Hong Qiu Han

http://www.w3.org/2001/XMLSchema#string

Ke Zhao

http://www.w3.org/2001/XMLSchema#string

Terron Anthony Hosten

http://www.w3.org/2001/XMLSchema#string

Xiang Hui He

http://www.w3.org/2001/XMLSchema#string

P2860

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

Shining a light on intestinal traffic

Review of inflammatory bowel disease in China

An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis

Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos

Pouchitis--recurrence of the inflammatory bowel disease?

Pouchitis: result of microbial imbalance?

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

Current and emerging drugs for the treatment of inflammatory bowel disease.

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

P304

51-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/GR599W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27785270

http://www.w3.org/2001/XMLSchema#string

P932

5051075

http://www.w3.org/2001/XMLSchema#string

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.

about

P2860

P2860

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932